Does sermorelin raise IGF-1?
Yes — typically modestly. Sermorelin is a growth hormone–releasing hormone analog that stimulates the pituitary to release endogenous GH, which raises IGF-1. The response is more physiologic and less suprapharmacologic than direct GH administration, which is the point.
Full answer
Yes — typically modestly. Sermorelin is a 29-amino-acid analog of growth hormone–releasing hormone (GHRH). It binds GHRH receptors on the anterior pituitary and stimulates pulsatile release of endogenous growth hormone, which then drives hepatic IGF-1 production. The IGF-1 rise on sermorelin is typically modest and preserves the pulsatile rhythm of natural GH release, in contrast to direct recombinant GH administration which produces a flatter, suprapharmacologic exposure. Sermorelin is provider-reviewed and used selectively — for adults with documented GH-axis decline and clinical symptoms — rather than universally. Response is monitored with IGF-1 (the stable downstream marker), alongside the broader biomarker panel and clinical symptom trajectory. Candidacy, dosing, and duration are individualized.
Educational. Not a substitute for individualized provider review.
- Sermorelin — Primary source · oMeds
- Reviewed by Dr. Laura Purdy, MD, MBA · Clinical Director, oMeds · Last reviewed 2026-05-29